Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. by Fernanda Amary, M et al.
ORIGINAL RESEARCH
Fibroblastic growth factor receptor 1 amplification in
osteosarcoma is associated with poor response to
neo-adjuvant chemotherapy
M. Fernanda Amary1,2, Hongtao Ye1, Fitim Berisha1, Bhavisha Khatri1, Georgina Forbes1, Katie
Lehovsky1, Anna M. Frezza2,3, Sam Behjati4, Patrick Tarpey4, Nischalan Pillay1,2, Peter J. Campbell4,
Roberto Tirabosco1, Nadege Presneau2, Sandra J. Strauss2,3 & Adrienne M. Flanagan1,2
1Histopathology, London Sarcoma Service, Royal National Orthopaedic Hospital NHS Trust, Stanmore, Middlesex, HA7 4LP, U.K.
2UCL Cancer Institute, Huntley Street, London, WC1E 6BT, U.K.
3University College London Hospitals Foundation Trust, London Sarcoma Service, 250 Euston Road, London, NW1 2PG, U.K.
4Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, U.K.
Keywords
Amplification, FGFR, FGFR1, FISH, genetics,
osteosarcoma, polysomy
Correspondence
Adrienne M. Flanagan, UCL – Cancer
Institute, 72 Huntley Street, London, WC1E
6BT, United Kingdom.
Tel: +4420 8909 5354;
Fax: +4420 8954 5908;
E-mail: a.flanagan@ucl.ac.uk
Funding Information
Skeletal Cancer Action Trust SCAT, UK, Bone
Cancer Research Trust, and the Wellcome
Trust (grant reference 077012/Z/05/Z).
Support was provided to AMF and SJS (UCL)
by the National Institute for Health Research,
University College London Hospitals
Biomedical Research Centre, and the UCL
Experimental Cancer Centre. P.J.C. is
personally funded through a Wellcome Trust
Senior Clinical Research Fellowship (grant
reference WT088340MA).
Received: 17 March 2014; Revised: 24 April
2014; Accepted: 30 April 2014
Cancer Medicine 2014; 3(4): 980–987
doi: 10.1002/cam4.268
Abstract
Osteosarcoma, the most common primary bone sarcoma, is a genetically com-
plex disease with no widely accepted biomarker to allow stratification of
patients for treatment. After a recent report of one osteosarcoma cell line and
one tumor exhibiting fibroblastic growth factor receptor 1 (FGFR1) gene amplifi-
cation, the aim of this work was to assess the frequency of FGFR1 amplification
in a larger cohort of osteosarcoma and to determine if this biomarker could be
used for stratification of patients for treatment. About 352 osteosarcoma sam-
ples from 288 patients were analyzed for FGFR1 amplification by interphase flu-
orescence in situ hybridization. FGFR1 amplification was detected in 18.5% of
patients whose tumors revealed a poor response to chemotherapy, and no
patients whose tumors responded well to therapy harbored this genetic alter-
ation. FGFR1 amplification is present disproportionately in the rarer histologi-
cal variants of osteosarcoma. This study provides a rationale for inclusion of
patients with osteosarcoma in clinical trials using FGFR kinase inhibitors.
Introduction
Osteosarcoma is the most common primary sarcoma of
bone, occurring rarely before the age of 4 years, and seen
most commonly in adolescents with a second peak in
adults, over 40 years of age. The vast majority of osteo-
sarcomas represents high-grade disease and behave in an
aggressive manner. The 5-year survival for patients with
appendicular high-grade disease who present without
metastases is ~60–70%, whereas prior to the introduction
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of neo-adjuvant chemotherapy only 20% of patients sur-
vived this period [1]. Histologically it is a heterogeneous
disease, with marked inter and intratumor variation [2].
It is also a genetically complex disease, with a high bur-
den of karyotypic abnormalities and a high level of geno-
mic instability [3]. Apart from the recurrent amplification
of MDM2, which is found in the majority of parosteal
osteosarcomas, for the most part a low-grade disease, and
in low-grade central osteosarcomas, there are no other
widely accepted biological markers which subclassify the
histological variants of osteosarcoma [2, 4].
Neo-adjuvant chemotherapy is the conventional treat-
ment for all histological variants of high-grade osteosar-
coma and response to such therapy is one of the most
powerful predictors of outcome in patients with resectable
disease [5]: a “good response” is classified as a tumor
showing 90% or more necrosis and ‘poor’ if there is less
than 90% tumor necrosis in response to chemotherapy.
Although there are several reports correlating gene expres-
sion with clinical outcome, which are useful in terms of
providing insight into the biology of the disease, none are
used in a clinical setting to determine clinical manage-
ment [6–11]. Indeed, there are no widely accepted bio-
markers employed for predicting response to therapy that
allow stratification of patients for treatment type [12].
Recently, it was reported that one of 7 osteosarcoma
cell lines, and one of 17 osteosarcomas harbored amplifi-
cation of fibroblastic growth factor receptor 1 (FGFR1), a
receptor tyrosine kinase located on chromosome 8p12,
which leads to activation of the Ras/mitogen-activated
protein kinase and PI3/Akt pathway, and ultimately lead-
ing to cell proliferation and differentiation [13]. The bio-
logical significance of this genetic alteration was
supported by inhibition of cell growth in the osteosar-
coma cell line, G292, harboring the FGFR1 amplification,
by the FGFR inhibitor, NVP-BGJ398, and was reinforced
by cell growth suppression following silencing of FGFR1
using shRNAs [13]. This report prompted us to assess the
frequency of FGFR1 amplification in a larger cohort of
osteosarcomas, with the aim of determining if this bio-
marker could be used for identifying a histological sub-
type/s of osteosarcoma that may benefit from treatment
with FGFR1 inhibitors, and also to determine if FGFR1
amplification would allow stratification of patients for
treatment with neo-adjuvant therapy and/or introduction
of specific FGFR inhibitors as a treatment option.
Materials and Methods
Ethical approval and samples
The samples were obtained from the Stanmore Musculo-
skeletal Biobank, approved by the Cambridgeshire
Research Ethics committee, Cambs., U.K.: Reference
Number: 09/H0304/78).
Tumor samples were retrieved through searching the
RNOH NHS Trust electronic histopathology database
between 2000 and 2012. The diagnoses were reviewed and
subtyped using the WHO classification (AMF, RT, MFA)
[2] and sections were selected for assessment of FGFR1
amplification. Tissue microarrays (TMAs) were con-
structed as previously reported using a manual tissue
arrayer (Beecher Instruments Inc, Sun Prairie, WI) using
at least two representative 1 mm cores of tumor [14]. All
tumors classified as “good responders” to chemotherapy
were analyzed on the pretreatment biopsy specimen. All
amplification-positive cases were analyzed in more than
one sample (pre and post –treatment, and recurrent dis-
ease) where tissue was available.
Fluorescence in situ hybridisation
FISH was performed using the commercially available
ZytoLight SPEC FGFR1/Centromere (CEN)8 Dual Color
Probe (ZytoVision, Bremerhaven, Germany). FGFR1
probes are labeled green and CEN8 orange. FISH was per-
formed as previously described. In brief, deparaffinised
sections were pretreated with deionized water in a pres-
sure cooker for 5 min and digested with pepsin at 37°C
for 50 min. Subsequently, the tissue sections and FGFR1/
CEN8 FISH probe were codenatured at 72°C for 10 min
and hybridized overnight at 37°C. Following hybridiza-
tion, washing was performed. Slides were then counter-
stained with 40, 6-diamidino-2-phenylindole (DAPI) and
mounted with coverslips.
At least 50 nonoverlapping nuclei were scored for the
number of FGFR1 and CEN8 copies at 1009 oil immer-
sion objective, after initial scanning of the section using a
409 objective to detect areas showing copy number varia-
tion after which areas with the highest copy number were
counted using a fluorescence microscope (Olympus BX61,
Southend-on-Sea, U.K.) equipped with appropriate filters,
a charge-coupled device camera (Olympus XM10), and
the FISH imaging and capturing software Cell* Imaging
system (Olympus Soft Imaging Solution, Germany).
Amplification was classified as positive if ≥10% of the
cells showed (a) FGFR1/CEN8 ratio >2, (b) clusters of
FGFR1 signals, or (c) >15 copies of FGFR1 per cell [15].
Tumors with polysomy of chromosome 8 comprised two
categories: high-level polysomy (≥4 copies of the gene of
interest and CEN8/cell in ≥40% of cells), and low-level
polysomy of chromosome 8 (>2 copies of the gene of
interest and CEN8/cell in ≤40% of cells, and 3 copies of
the gene of interest per cell in ≥40% of cells). Disomy
was defined as two copies of the gene of interest and
CEN8 in >90% of the cells.
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The FISH slides were assessed by HY and FB indepen-
dently. If there were a discrepancy, the slides were reviewed
by MFA and AMF and a consensus was reached. If a result
was equivocal, the FISH was repeated on a full tissue sec-
tion. All equivocal cases were reviewed by MFA and AMF.
Patient characteristics and outcome analysis
Clinical details including age, sex, site of primary tumor,
and presence and absence of metastases were collated
from pathology and patient records where available.
A retrospective outcome analysis was performed on
patients with extremity tumors who were known to have
received chemotherapy and where follow-up information
was available. The analysis was therefore not of consecu-
tive patients treated within the London Sarcoma Service
(LSS), and included patients treated outside the service.
Patients received standard chemotherapy regimens
according to local and clinical trial protocols in use at the
time of diagnosis. This incorporated cisplatin and doxo-
rubicin in older patients (over 40 years) or those treated
in the early 2000s. The majority of patients received MAP
(methotrexate, doxorubicin, and cisplatin). Overall
survival (OS) was calculated as the period from diagnosis
to death or last follow-up. Descriptive analysis was made
using median values and range. Survival analysis was
performed by Kaplan–Meier product-limit method and
the differences in term of OS according to pathological
response were evaluated by the log-rank test. SPSS
software (version 17.00, SPSS, Chicago, IL) was used
for statistical analysis. A P value of less than 0.05 was
considered to indicate statistical significance.
Results
To investigate FGFR1 amplification in osteosarcoma, we
evaluated a total of 352 samples from 288 patients. About
275 with osteosarcomas arising in bone and 13 arising in
soft tissue gave informative results for FGFR1/CEN8
FISH. The cohort of patients with bone tumors included
119 “poor responders” and 80 “good responders” to neo-
adjuvant chemotherapy. The remaining patients (n = 76)
had either not been exposed to neo-adjuvant therapy
(n = 57) or the response to therapy was not available
(n = 19) (Table 1).
FGFR1 gene amplification was detected in 24 (9.6%) of
275 osteosarcomas arising in bone (Fig. 1). This included
22 (18.5%) of 119 “poor responders”, whereas no tumor
which revealed a “good response” to neo-adjuvant che-
motherapy (n = 109) exhibited FGFR1 amplification
(Table 2). In four of these 22 cases, samples from meta-
static disease were available which also revealed FGFR1
amplification.
One of 57 (1.7%) bone osteosarcomas not treated with
neo-adjuvant chemotherapy, and one radiation-induced
osteosarcoma of 19 (5.3%) bone osteosarcomas on which
treatment information was not available also revealed
FGFR1 amplification.
Of the total cohort of 288 patients, 22 had a radiation-
induced bone osteosarcoma, 3 (13.6%) of which showed
FGFR1 gene amplification. In none of these cases was the
original tumor material available to assess for the pres-
ence of FGFR1 amplification. Seven (31.8%) of the radia-
tion-induced osteosarcomas revealed c-MYC amplification
(Table 3). Also included in the study were 26 surface
osteosarcomas (Table 1), 20 of which had not received
neo-adjuvant chemotherapy. FGFR1 amplification was
detected in only one of these 26 cases (6.8%), and this
tumor was a periosteal osteosarcoma. No low-grade cen-
tral osteosarcoma and no Pagetic osteosarcomas exhibited
FGFR1 gene amplification.
We next performed a more detailed analysis of the
common subtypes of osteosarcoma, excluding surface,
low-grade central, and secondary osteosarcomas (radia-
tion-induced and Pagetic sarcomas) [2]. This group
included 232 tumor samples from 184 patients with cen-
tral high-grade osteosarcomas, comprising 75 “good
responders” and 109 “poor responders”. The clinical char-
acteristics of these cases are summarized in Table 1 and
Table S1. The median age at diagnosis of this group was
16 years (range 4–64 years), with a 1.83:1 male to female
ratio. Nineteen patients had tumor samples with FGFR1
gene amplification. Of these 19 patients, 13 were male
and 6 female. The median age at presentation in this
group was 17 years (range 8–56).
The histological subtypes of the 184 patients with com-
mon forms of osteosarcomas are shown in Table 2. The
subtype distribution in the total cohort are similar to that
described in the literature [2]. However, FGFR1 amplifi-
cation was found to be present disproportionately in the
more rare histological variants of osteosarcoma (Table 2)
(P < 0.002). The femur was the most common site for
tumors, irrespective of whether they harbored FGFR1
amplification, and all FGFR1 amplified tumors arose in
the extremities. Staging data were available for 133
patients of whom 26 (19.7%) had metastatic disease at
diagnosis. Although patients with tumors harboring
FGFR1 amplification had a higher incidence of metastases
(24% vs. 18%), this was not significantly different from
those that did not have FGFR1 amplification (P = 0.553).
Clinical outcome data were available for 144 of 176
patients with extremity tumors including all 19 patients
with FGFR1 amplification. Patients with a poor response
to chemotherapy had an inferior outcome with a median
OS of 43 months (95% CI 21.9–64) compared to patients
whose tumors showed a good response where the median
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survival has not been reached after a median follow-up of
33 months (P < 0.001) (Fig. 2). Patients with FGFR1
amplification had an equivalent outcome to other patients
with a poor response (P = 0.091). There was no differ-
ence in outcome of patients with polysomy CEN8 versus
nonpolysomy or between those with >6 copies and <6
copies (Table S2, P = 0.2 and P = 0.39, respectively).
Only 30% of the bone osteosarcomas were diploid for
CEN8 (Table 4). The details of these findings in relation
to the morphological subtype are found in Table 4.
FGFR1 amplification was detected in two of 13 soft tissue
osteosarcomas (Table 1).
Discussion
We report the occurrence of FGFR1 gene amplification in
osteosarcoma. We found that this genetic alteration is
detected in ~10% of all bone osteosarcomas by interphase
Table 1. Correlation of data from 288 patients including osteosar-
coma histological phenotype, response to neo-adjuvant chemother-
apy, and the presence and absence of FGFR1 amplification.
Osteosarcoma
details
Histological
subtype (n)
FGFR1
amplification
negative
FGFR1
amplification
positive
Good response2
(N = 80)
Osteoblastic (48) 48 0
Chondroblastic (19) 19 0
Fibroblastic/
Pleomorphic (5)
5 0
Telangiectatic (6) 6 0
Periosteal (1) 1 0
High-grade
surface (1)
1 0
Total 80 0
Poor response2
(N = 119)
Osteoblastic (61) 54 7
Chondroblastic (24) 20 4
Fibroblastic/
Pleomorphic (18)
10 8
Telangiectatic (8) 6 2
Rare subtypes1 (4) 4 0
Periosteal (3) 2 1
Parosteal (1) 1 0
Total 97 22
Soft tissue
osteosarcoma
(N = 13)
Soft tissue
osteosarcoma
11 2
NCG or
unknown2
(N = 76)
Parosteal (15) 15 0
Periosteal (4) 4 0
High-grade
surface (1)
1 0
Osteoblastic (18) 18 0
Chondroblastic (6) 5 1
Fibroblastic/
Pleomorphic (13)
12 1
Telangiectatic (6) 6 0
Low-grade
central (7)
7 0
Rare subtypes1 (6) 6 0
Total 74 2
The shaded area highlights surface osteosarcomas.
NCG, No chemotherapy given.
1Osteoblastoma-like, giant-cell rich, fibrous-dysplasia-like.
2Bone osteosarcomas.
A
B
C
Figure 1. Photomicrographs of FISH for FGFR1/CEN8 showing
clusters of FGFR1 signals (A), FGFR/CEN8 ratio >2 (B) and >15 copies
of FGFR (C).
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FISH. Within our cohort of 184 patients with central high-
grade osteosarcomas who received neo-adjuvant chemo-
therapy, FGFR1 gene amplification was exclusively detected
among the “poor responder” group and represented 17.4%
of patients in this group. Because of the relatively small
number of cases with FGFR1 amplification in this study, it
is not possible to determine whether the survival of this
patient group is significantly different to the group of
“poor responders” as a whole, and whether FGFR1 amplifi-
cation in osteosarcoma contributes to the risk of metastatic
disease. The cohort included patients with metastatic dis-
ease at diagnosis which may confound the outcome analy-
sis because a higher percentage of patients with a poor
response had documented metastases at presentation (22%
vs. 15%), this difference was not significant (P = 0.261).
Nevertheless, FGFR1 gene amplification identifies a
Table 2. Morphological subtypes of classic variants of primary central high-grade osteosarcomas treated with neo-adjuvant chemotherapy: corre-
lation with response to neo-adjuvant chemotherapy and presence of FGFR1 amplification.
Osteosarcoma subtype
Osteoblastic
105 (57.1%)
Chondroblastic
40 (21.7%)
Fibroblastic
21 (11.4%)
Telangiectatic
14 (7.6%)
Others
4 (2.2%)
Total 184
(100%)
Number of “Good responders” (%) 45 19 5 6 0 75 (40.8)
Number of ‘Poor responders’ (%) 60 21 16 8 4 109 (59.2)
Number of cases with amplification
(% of subtype)1
7 (6.7) 3 (7.5) 7 (33.3) 2 (14.3) 0 19
1All cases with FGFR1 amplification showed a poor response to neo-adjuvant chemotherapy.
Table 3. Details of radiation-induced osteosarcoma.
Neo-adjuvant
treatment
status Gender
Age at
diagnosis Site Subtype
Primary irradiated tumor;
year of treatment
FGFR1 FISH
copy number
c-MYC copy
number
MGORSP M 46 Femur Osteoblastic Fibrosarcoma; 1968 DI DI
MPORSP M 52 Pelvis Fibroblastic Giant-cell tumor of bone;
Right Pubis; 1980
AMP Poly (H)
MPORSP F 69 Pelvis Chondroblastic Carcinoma; cervix; 1985 DI Poly (H)
NK M 15 Skull Osteoblastic Medulloblastoma; posterior fossa; 1997 Poly (L) AMP
MPORSP F 26 Scapula Chondroblastic Rhabdomysosarcoma; chest wall; 1984 AMP AMP
NK F 63 Ilium Chondroblastic Squamous cell carcinoma; cervix; 1987 AMP Poly (L)
MPORSP M 34 Femur Chondroblastic Ewing sarcoma; femur; 1998 Poly (H) AMP
MPORSP F 70 Pelvis Fibroblastic Squamous cell carcinoma;
anal canal; 1993
Poly (H) AMP
NK M 56 Mandible Osteoblastic Bilateral acinic cell carcinoma;
parotid glands; 2005
Poly (L) Poly (H)
NK M 33 Iliac crest Osteoblastic Hodgkin’s lymphoma; 1992 DI Poly (L)
NK F 38 Sacrum Osteoblastic Carcinoma; cervix; 2006 DI DI
NCG F 70 Humerus Osteoclast-rich Carcinoma; ductal; 1990 Poly (H) Poly (H)
MPORSP M 15 Mandible Osteoblastic Rhabdomyosarcoma;
temporalis; 1995
Poly (L) Poly (L)
NK F 60 Vertebra Osteoblastic Myeloma; unknown DI AMP
NK M 68 Skull Fibroblastic Squamous cell Carcinoma;
maxilla; 2000
Poly (L) Poly (L)
MGORSP M 19 Mandible Osteoblastic Rhabdomyosarcoma; ethmoid; 1991 DI DI
NK F 63 Chest wall Osteoblastic Carcinoma; brest; 2002 Poly (H) Poly (H)
NK M 46 Mandible Fibroblastic Squamous cell carcinoma;
mouth; 2003
Poly (H) Poly (L)
NK M 46 Sacrum Chondroblastic Carcinoma; rectal; 1997 Poly (L) Poly (L)
NK M 50 Mandible Chondroblastic Squamous cell carcinoma; tongue; 1990 Poly (H) Poly (H)
NK M 72 Skull Telangiectatic Bilateral retinoblastoma; 1935 DI DI
NK F 48 Chest wall Chondroblastic Carcinoma; breast; 1987 DI AMP
Poor response, MGORSP. NCG, not treatment with chemotherapy. Not known, NK. DI, disomic. Poly (H), high-level polysomy. Poly (L), low-level
polysomy. AMP, gene amplification.
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subgroup of patients who could potentially benefit from
treatment with inhibitors to FGFR1.
The other significant finding of this study was that the
presence of FGFR1 amplification occurs disproportion-
ately in the less common histological subtypes, with the
highest percentage (25%) of FGFR1 amplified cases
occurring in the fibroblastic/pleomorphic subtype [2].
Importantly, the spectrum and incidence of osteosarcoma
subtypes in our tumor set is similar to that in the pub-
lished literature, and therefore our data are not biased
toward a particular histological variant [2].
FGFR1 gene amplification was reported firstly as a
potential therapeutic target in breast cancer [16–18].
Amplification of the gene encoding this receptor was
also detected in a number of other cancers including
lung (10–22%), ovarian, and head and neck carcinomas
[19–24]. Similar to our finding in osteosarcoma, FGFR1
amplification is associated with poor clinical outcome in
a number of these tumor types. In particular, it was
found to be the strongest independent predictor of poor
outcome in estrogen receptor-positive breast cancer [16,
25]. Furthermore, FGFR1 amplification in ovarian serous
carcinoma is associated with increased angiogenesis,
metastatic disease, and overall poor survival [24]. This
is the first study, however, to demonstrate specifically
an association of FGFR1 amplification with lack of
response to chemotherapy. Further investigation of a
role for FGFR1 amplification in predicting chemoresis-
tance and a potential mechanism for this is, therefore,
warranted.
It is noteworthy that much of our understanding of
FGF signaling in skeletal development has been obtained
through study of germline alterations in the various
FGFRs, which give rise to skeletal dysplasias. However,
there is no evidence that such mutations are associated
with the development of skeletal cancer [26].
Table 4. Bone osteosarcoma cohort (275 patients) by subtype correlated with copy number status.
Histological subtype (n) Diploid Poly (H) Poly (L)
FGFR1
Amp
FGFR1 AMP%
by subtype
Osteoblastic (127) 34 50 36 7 5.5
Chondroblastic (49) 15 20 9 5 10.2
Fibroblastic/Pleomorphic (36) 5 15 7 9 25
Telangiectatic (20) 6 8 4 2 10
Unusual subtypes (10) 6 2 2 0 –
Low-grade central (7) 5 2 0 0 –
Surface (26) 14 5 6 1 6.8
Total (275) 85 (30.9%) 102 (37.1%) 64 (23.3%) 24 (8.7%)
Poly (H), high-level polysomy; Poly (L), low-level polysomy; AMP, gene amplification.
A B
Figure 2. Kaplan–Meier overall survival (OS) curves of 144 osteosarcoma patients treated with neo-adjuvant chemotherapy according to response
to chemotherapy (A). GR, good response; PR, poor response. Kaplan–Meier OS curves of patients with a poor response to chemotherapy
according FGFR status (FGFR1+ = FGFR1 amplification) (B).
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The study by Guagnano et al. reported that the one
osteosarcoma cell line which responded to anti-FGFR
treatment in their in vitro study had FGFR amplification
detected by qPCR. On analyzing the same cell line by
FISH in our laboratory, we confirmed the presence of
amplification by detecting 4:1 FGFR1/CEN8 ratio.
The difficulty in defining gene copy number as a pre-
dictive biomarker for stratification of patients for targeted
therapy is well recognized even with established actionable
targets, such as HER2 in breast cancer. Here, even after
many years of use within clinical practice there is still no
consensus defining which level of copy number gain pre-
dicts the response to inhibitors [27–29]. Well-designed
clinical studies correlated with gene copy number for
which there are strict and reproducible scoring criteria
should provide an evidence base for patient stratification.
In the study by Guagnano et al., it was also demon-
strated that the FGFR-kinase inhibitor exerted no effect
on 54% (n-20) of cell lines harboring FGFR1 amplifica-
tion. In some of these tumors, additional alterations were
detected including mutations in KRAS (n = 4), and
BRAF, and amplification of HER2, which may contribute
to the resistance to the FGFR-kinase inhibitor [13]. These
findings emphasize that, as technology develops, patients
may benefit from more global genomic analysis of tumor
samples prior to treating with targeted compounds.
This is the first study to show a genetic alteration in
osteosarcomas that is associated with a poor response to
neo-adjuvant chemotherapy. Although prospective valida-
tion of results is warranted, a number of FGFR1 inhibi-
tors are currently in clinical development, and phase II
biomarker-driven studies are already underway in several
solid tumors http://clinicaltrials.gov/ct2/show/NCT0176
1747?term=NCT01761747&rank=1.
This study provides a rationale for inclusion of osteo-
sarcoma patients in such studies. The challenge will be
how best to determine selection criteria for their inclu-
sion, and how to encourage pharmaceutical companies to
undertake clinical trials involving this rare cancer.
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